array:25 [
  "pii" => "S2341287919301760"
  "issn" => "23412879"
  "doi" => "10.1016/j.anpede.2019.01.016"
  "estado" => "S300"
  "fechaPublicacion" => "2019-12-01"
  "aid" => "2598"
  "copyright" => "Asociación Española de Pediatría"
  "copyrightAnyo" => "2019"
  "documento" => "simple-article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "crp"
  "cita" => "An Pediatr (Barc). 2019;91:411-3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 175
    "formatos" => array:3 [
      "EPUB" => 30
      "HTML" => 109
      "PDF" => 36
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S1695403319300293"
      "issn" => "16954033"
      "doi" => "10.1016/j.anpedi.2019.01.012"
      "estado" => "S300"
      "fechaPublicacion" => "2019-12-01"
      "aid" => "2598"
      "copyright" => "Asociación Española de Pediatría"
      "documento" => "simple-article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "crp"
      "cita" => "An Pediatr (Barc). 2019;91:411-3"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 1561
        "formatos" => array:3 [
          "EPUB" => 100
          "HTML" => 1084
          "PDF" => 377
        ]
      ]
      "es" => array:11 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Carta cient&#237;fica</span>"
        "titulo" => "Arteritis de Takayasu de presentaci&#243;n at&#237;pica&#46; Tocilizumab como alternativa terap&#233;utica"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "411"
            "paginaFinal" => "413"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Takayasu arteritis of atypical presentation&#46; Tocilizumab as an alternative therapeutic option"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 635
                "Ancho" => 1255
                "Tamanyo" => 100672
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A&#41; Angio-TC&#46; Estenosis arteria subclavia y vertebral izquierdas&#44; aorta abdominal y arterias renales derechas&#46; B&#41; Arteriograf&#237;a de arteria aorta&#46; Ri&#241;&#243;n derecho con bifurcaci&#243;n de arteria renal y estenosis cr&#237;tica en su <span class="elsevierStyleItalic">ostium</span> y ri&#241;&#243;n izquierdo con arteria renal sin signos de estenosis&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Zaira Cubiles Arillo, Esmeralda N&#250;&#241;ez Cuadros, Ver&#243;nica Mart&#237;nez Rivera, Jos&#233; Manuel Gonz&#225;lez G&#243;mez, Victorio Cuenca Peir&#243;"
            "autores" => array:5 [
              0 => array:2 [
                "nombre" => "Zaira"
                "apellidos" => "Cubiles Arillo"
              ]
              1 => array:2 [
                "nombre" => "Esmeralda"
                "apellidos" => "N&#250;&#241;ez Cuadros"
              ]
              2 => array:2 [
                "nombre" => "Ver&#243;nica"
                "apellidos" => "Mart&#237;nez Rivera"
              ]
              3 => array:2 [
                "nombre" => "Jos&#233; Manuel"
                "apellidos" => "Gonz&#225;lez G&#243;mez"
              ]
              4 => array:2 [
                "nombre" => "Victorio"
                "apellidos" => "Cuenca Peir&#243;"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2341287919301760"
          "doi" => "10.1016/j.anpede.2019.01.016"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287919301760?idApp=UINPBA00005H"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403319300293?idApp=UINPBA00005H"
      "url" => "/16954033/0000009100000006/v2_201912170939/S1695403319300293/v2_201912170939/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2341287919301851"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2019.10.002"
    "estado" => "S300"
    "fechaPublicacion" => "2019-12-01"
    "aid" => "2719"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "An Pediatr &#40;Barc&#41;. 2019;91:414&#46;e1-414&#46;e6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 125
      "formatos" => array:3 [
        "EPUB" => 30
        "HTML" => 73
        "PDF" => 22
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Spanish Association of Paediatrics</span>"
      "titulo" => "&#171;I prepare my rotation by&#187;&#44; a virtual complement of paediatric specialist training"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "414&#46;e1"
          "paginaFinal" => "414&#46;e6"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "&#171;Preparo mi rotaci&#243;n por&#187;&#44; complemento virtual de la formaci&#243;n mir en pediatr&#237;a"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Francisco Hijano Bandera, Javier Gonz&#225;lez de Dios, M&#46; Rosa Pavo Garc&#237;a, Esteban Peir&#243; Molina, Carmen Villaiz&#225;n P&#233;rez, Carlos Ochoa Sangrador, M&#46; Jos&#233; Mellado Pe&#241;a"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "Francisco Hijano"
              "apellidos" => "Bandera"
            ]
            1 => array:2 [
              "nombre" => "Javier Gonz&#225;lez"
              "apellidos" => "de Dios"
            ]
            2 => array:2 [
              "nombre" => "M&#46; Rosa Pavo"
              "apellidos" => "Garc&#237;a"
            ]
            3 => array:2 [
              "nombre" => "Esteban Peir&#243;"
              "apellidos" => "Molina"
            ]
            4 => array:2 [
              "nombre" => "Carmen Villaiz&#225;n"
              "apellidos" => "P&#233;rez"
            ]
            5 => array:2 [
              "nombre" => "Carlos Ochoa"
              "apellidos" => "Sangrador"
            ]
            6 => array:2 [
              "nombre" => "M&#46; Jos&#233; Mellado"
              "apellidos" => "Pe&#241;a"
            ]
            7 => array:1 [
              "colaborador" => "Coordinadores de Continuum"
            ]
            8 => array:1 [
              "colaborador" => "Coordinadores de Continuum&#44; Alberto Garc&#237;a Salido&#44; Jos&#233; Mar&#237;a Garrido Pedraz&#44; Manuel Molina Arias&#44; Manuel Praena Crespo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287919301851?idApp=UINPBA00005H"
    "url" => "/23412879/0000009100000006/v1_201912080648/S2341287919301851/v1_201912080648/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2341287919301802"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2019.01.017"
    "estado" => "S300"
    "fechaPublicacion" => "2019-12-01"
    "aid" => "2606"
    "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "An Pediatr &#40;Barc&#41;. 2019;91:410-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 169
      "formatos" => array:3 [
        "EPUB" => 19
        "HTML" => 113
        "PDF" => 37
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
      "titulo" => "Cold urticaria and coeliac disease in a paediatric patient"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "410"
          "paginaFinal" => "411"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Urticaria por fr&#237;o y enfermedad celiaca en paciente pedi&#225;trico"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alejandra M&#233;ndez S&#225;nchez, Alicia Isabel Pascual P&#233;rez, Maria Antonia V&#225;zquez Pi&#241;era, Porfirio Fern&#225;ndez Gonz&#225;lez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Alejandra"
              "apellidos" => "M&#233;ndez S&#225;nchez"
            ]
            1 => array:2 [
              "nombre" => "Alicia Isabel"
              "apellidos" => "Pascual P&#233;rez"
            ]
            2 => array:2 [
              "nombre" => "Maria Antonia"
              "apellidos" => "V&#225;zquez Pi&#241;era"
            ]
            3 => array:2 [
              "nombre" => "Porfirio"
              "apellidos" => "Fern&#225;ndez Gonz&#225;lez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1695403319300694"
        "doi" => "10.1016/j.anpedi.2019.01.018"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403319300694?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287919301802?idApp=UINPBA00005H"
    "url" => "/23412879/0000009100000006/v1_201912080648/S2341287919301802/v1_201912080648/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>"
    "titulo" => "Takayasu arteritis of atypical presentation&#46; Tocilizumab as an alternative therapeutic option"
    "tieneTextoCompleto" => true
    "saludo" => "Dear Editor&#58;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "411"
        "paginaFinal" => "413"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Zaira Cubiles Arillo, Esmeralda N&#250;&#241;ez Cuadros, Ver&#243;nica Mart&#237;nez Rivera, Jos&#233; Manuel Gonz&#225;lez G&#243;mez, Victorio Cuenca Peir&#243;"
        "autores" => array:5 [
          0 => array:4 [
            "nombre" => "Zaira"
            "apellidos" => "Cubiles Arillo"
            "email" => array:1 [
              0 => "zaira915@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor1"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Esmeralda"
            "apellidos" => "N&#250;&#241;ez Cuadros"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Ver&#243;nica"
            "apellidos" => "Mart&#237;nez Rivera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Jos&#233; Manuel"
            "apellidos" => "Gonz&#225;lez G&#243;mez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Victorio"
            "apellidos" => "Cuenca Peir&#243;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:5 [
          0 => array:3 [
            "entidad" => "Unidad de Gesti&#243;n Cl&#237;nica de Pediatr&#237;a&#44; Hospital Materno Infantil&#44; Hospital Regional Universitario de M&#225;laga&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Unidad de Reumatolog&#237;a Pedi&#225;trica&#44; Unidad de Gesti&#243;n Cl&#237;nica de Pediatr&#237;a&#44; Hospital Materno Infantil&#44; Hospital Regional Universitario de M&#225;laga&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Unidad de Nefrolog&#237;a Pedi&#225;trica&#44; Unidad de Gesti&#243;n Cl&#237;nica de Pediatr&#237;a&#44; Hospital Materno Infantil&#44; Hospital Regional Universitario de M&#225;laga&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Unidad de Cuidados Intensivos Pedi&#225;tricos&#44; Unidad de Gesti&#243;n Cl&#237;nica de Cuidados Cr&#237;ticos y Urgencias Pedi&#225;tricas&#44; Hospital Materno Infantil&#44; Hospital Regional Universitario de M&#225;laga&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Unidad de Cardiolog&#237;a Pedi&#225;trica&#44; Unidad de Gesti&#243;n Cl&#237;nica de Pediatr&#237;a&#44; Hospital Materno Infantil&#44; Hospital Regional Universitario de M&#225;laga&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor1"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Arteritis de Takayasu de presentaci&#243;n at&#237;pica&#46; Tocilizumab como alternativa terap&#233;utica"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 755
            "Ancho" => 1500
            "Tamanyo" => 127883
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Computed tomography angiogram&#46; Stenosis of left subclavian and vertebral arteries&#44; abdominal aorta and right renal arteries&#46; &#40;B&#41; Arteriogram of the aorta&#46; Right kidney with renal artery bifurcation and critical stenosis in the ostium&#44; and left kidney with no signs of stenosis of the renal artery&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Takayasu arteritis &#40;TA&#41; is a granulomatous large vessel vasculitis that is infrequent in children&#46; It usually has onset with headache&#44; fever&#44; abdominal pain or hypertension &#40;HTN&#41;&#46; In rare cases&#44; onset occurs with heart failure&#44; which has only been described in 18&#37; of paediatric cases&#46; There has been recent evidence of the involvement of interleukin-6 &#40;IL-6&#41; in its pathogenesis&#44; whose levels appear elevated in serum and the arterial wall&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The diagnosis of TA requires the presence of angiographic abnormalities in addition to at least 1 out of 5 criteria &#40;EULAR&#47;PRINTO&#47;PRES criteria&#44; <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">2</span></a> Although computed tomography angiography &#40;CTA&#41; is the gold standard of imaging&#44; as it allows visualization of blood flow and the extent of collateralization&#44; it does not provide any information about the arterial wall&#46; Thus&#44; a magnetic resonance angiography &#40;MRA&#41; is also useful to assess abnormalities of the vessel wall&#44; and its results correlate to clinical manifestations and inflammatory marker levels&#46; Positron emission tomography&#47;computer tomography &#40;PET-CT&#41; is not indicated for routine assessment&#44; but it may be useful in patients with negative inflammatory markers&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">2</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Treatment is delivered in 2 phases&#58; induction and maintenance&#46; In case of haemodynamic instability&#44; the induction phase consists of steroids delivered by intravenous pulse initially followed by oral administration combined with an immunosuppressive agent &#40;cyclophosphamide or methotrexate&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">3</span></a> The agents used in the maintenance phase include methotrexate&#44; mycophenolate mofetil or azatioprine&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">3</span></a> In recent years&#44; new treatments have been proposed for refractory cases&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">2&#44;4&#8211;6</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">We present the case of a patient with TA with onset of heart failure that eventually required biological therapy with anti-IL6&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The patient was a girl aged 11 years presenting with vomiting and abdominal pain with onset 10 days prior associated with asthenia of a few weeks&#8217; duration&#46; The physical examination revealed pallor in the skin and mucosae&#44; acral coldness&#44; difficulty breathing&#44; hypoventilation and bibasilar crackles&#44; a gallop rhythm &#40;heart rate&#44; 140 bpm&#41;&#44; an oxygen saturation &#40;SatO<span class="elsevierStyleInf">2</span>&#41; of 90&#37; and hepatomegaly&#46; The left radial and brachial pulses were absent&#44; with a blood pressure &#40;BP&#41; of 80&#47;50 in the left arm &#40;below the 50th percentile&#41; and 140&#47;100 in the right arm &#40;above the 99th percentile&#41;&#46; The salient laboratory features were a haemoglobin concentration &#40;Hb&#41; of 9&#46;9<span class="elsevierStyleHsp" style=""></span>g&#47;dL&#44; a platelet count of 636<span class="elsevierStyleHsp" style=""></span>000&#47;mm<span class="elsevierStyleSup">3</span> and a C-reactive protein &#40;CPR&#41; level of 20<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#46; The chest radiograph revealed cardiomegaly with signs of acute pulmonary oedema&#44; and the electrocardiogram featured signs of atrial enlargement and left ventricular hypertrophy&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">The patient was admitted to the PICU with a diagnosis of acute heart failure and assessed by means of an echocardiogram that revealed severe systolic failure &#40;forced expiratory volume in 1 second &#91;FEV<span class="elsevierStyleInf">1</span>&#93;&#44; 20&#37;&#41; and mild mitral valve regurgitation&#46; Haemodynamic support was initiated with milrinone&#44; diuretics and levosimendan&#44; and respiratory support with BIPAP&#44; to which the patient responded favourably&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">An abdominal ultrasound examination revealed signs of aortitis&#44; and since TA was suspected&#44; the investigation was completed with a CT angiogram &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>A&#41; that showed thickening of the left subclavian artery with significant stenosis and narrowing at the outlet of the left vertebral artery with collateralization&#44; as well as thickening in segments of the thoracic and abdominal aorta and stenosis of the right renal arteries&#46; Magnetic resonance angiography confirmed the acute involvement of the subclavian and vertebral arteries&#44; and the chronic involvement of the aorta and its branches&#46; The patient received a diagnosis of TA type V and started treatment with boluses of methylprednisolone at a dose of 30<span class="elsevierStyleHsp" style=""></span>mg&#47;kg for 3 days &#40;followed by prednisone at a dose of 2<span class="elsevierStyleHsp" style=""></span>mg&#47;kg&#47;day&#41; and intravenous cyclophosphamide at a dose of 500<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> every 3 weeks&#44; which achieved normalization of laboratory parameters after the second dose&#46; The patient&#39;s blood pressure remained above the 99th percentile despite a combination of 6 drugs&#44; so&#44; following performance of an arteriogram &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>B&#41;&#44; the patient underwent a right renal artery angioplasty that allowed the discontinuation of 4 drugs and achieved adequate control of the blood pressure&#46; Two months later&#44; there was evidence of elevation of CRP &#40;46<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#41;&#44; the ESR &#40;77<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#41; and serum levels of IL-6 &#40;29&#46;4<span class="elsevierStyleHsp" style=""></span>pg&#47;mL&#41;&#44; so after administration of 5 doses of cyclophosphamide&#44; treatment was initiated with anti-IL-6 &#40;tocilizumab iv 8<span class="elsevierStyleHsp" style=""></span>mg&#47;kg every 2 weeks&#41;&#46; The patient exhibited a good response after 2 doses&#44; with normalization of laboratory tests and a decrease in the levels of IL-6 &#40;35<span class="elsevierStyleHsp" style=""></span>pg&#47;mL&#41;&#46; Twelve months later&#44; the patient was asymptomatic&#44; with a FEV<span class="elsevierStyleInf">1</span> 70&#37; without treatment with antihypertensive drugs&#44; so&#44; on confirmation of stabilization by imaging&#44; the interval between doses of tocilizumab was increased to 3 weeks&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">In addition to the control of HTN&#44; which may be complicated and in some cases require invasive interventions such as renal artery angioplasty&#44;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">4</span></a> the patient must remain under strict monitoring of other cardiovascular risk factors&#44; such as hypercholesterolemia and hypercoagulability&#46; Our patient required rosuvastatin and acetylsalicylic acid&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">The challenge in the management of TA is to differentiate between the active and chronic phases&#44; as there are no specific markers of disease activity&#46; The sensitivity and the specificity of CRP and ESR values are low&#44; so other biomarkers are currently being investigated&#44; such as matrix metalloproteinases &#40;MMPs&#41;&#44; vascular cell adhesion proteins &#40;VCAM&#41;&#44; the inverted CD4&#47;CD8 ratio and pentraxin 3&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">5</span></a> However&#44; there is evidence of a correlation between the levels of IL-6 and disease activity&#44; which suggests that this cytokine may be a useful target for treatment&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">1&#44;5&#44;6</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Although conventional treatment continues to be widespread&#44; several case series have been published that demonstrate the effectiveness of biological agents such as anti-TNF-&#945; &#40;infliximab&#47;adalimumab&#41; or anti-IL6 &#40;tocilizumab&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">4&#8211;6</span></a> These studies have reported a mean time to resolution of symptom of 3 months in the absence of severe side effects&#44; in addition to allowing a reduction of the steroid dose&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Cubiles Arillo Z&#44; N&#250;&#241;ez Cuadros E&#44; Mart&#237;nez Rivera V&#44; Gonz&#225;lez G&#243;mez JM&#44; Cuenca Peir&#243; V&#46; Arteritis de Takayasu de presentaci&#243;n at&#237;pica&#46; Tocilizumab como alternativa terap&#233;utica&#46; An Pediatr &#40;Barc&#41;&#46; 2019&#59;91&#58;411&#8211;413&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 755
            "Ancho" => 1500
            "Tamanyo" => 127883
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Computed tomography angiogram&#46; Stenosis of left subclavian and vertebral arteries&#44; abdominal aorta and right renal arteries&#46; &#40;B&#41; Arteriogram of the aorta&#46; Right kidney with renal artery bifurcation and critical stenosis in the ostium&#44; and left kidney with no signs of stenosis of the renal artery&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Angiographic abnormalities &#40;conventional&#44; CT or MR imaging&#41; of the aorta or its main branches and pulmonary arteries showing aneurysm&#47;dilatation&#44; narrowing&#44; occlusion or thickened arterial wall not due to fibromuscular dysplasia or similar causes &#40;mandatory criterion&#41; plus one of the following 5 criteria&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46; Pulse deficit or claudication&#58; lost&#47;decreased&#47;unequal peripheral artery pulses or claudication &#40;focal muscle pain induced by physical activity&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46; Blood pressure discrepancy&#58; discrepancy of four limb systolic blood pressure<span class="elsevierStyleHsp" style=""></span>&#62; 10<span class="elsevierStyleHsp" style=""></span>mmHg difference in any limb&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46; Bruits&#58; audible murmurs or palpable thrills over large arteries&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46; Hypertension&#58; systolic&#47;diastolic blood pressure greater than 95<span class="elsevierStyleSup">th</span> percentile for height&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46; Acute phase reactants&#58; ESR<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>20<span class="elsevierStyleHsp" style=""></span>mm per first hour or any value of CRP above normal &#40;according to the local laboratory&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2177027.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">EULAR&#47;PRINTO&#47;PRES criteria for childhood Takayasu arteritis&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:6 [
            0 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Childhood-onset Takayasu arteritis&#58; an update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;J&#46; Mathew"
                            1 => "R&#46; Goel"
                            2 => "S&#46; Kumar"
                            3 => "D&#46; Danda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/1756-185X.12718"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Rheum Dis"
                        "fecha" => "2016"
                        "volumen" => "19"
                        "paginaInicial" => "116"
                        "paginaFinal" => "126"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26585174"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EULAR&#47;PRINTO&#47;PRES criteria for Henoch-Sch&#246;nlein purpura&#44; childhood polyarteritis nodosa&#44; childhood Wegener granulomatosis and childhood Takayasu arteritis&#58; Ankara 2008&#46; Part II&#58; Final classification criteria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Ozen"
                            1 => "A&#46; Pistorio"
                            2 => "S&#46;M&#46; Lusan"
                            3 => "A&#46; Bakkaloglu"
                            4 => "T&#46; Herlin"
                            5 => "R&#46; Brik"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2009.116657"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2010"
                        "volumen" => "69"
                        "paginaInicial" => "798"
                        "paginaFinal" => "806"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20413568"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0735109710026380"
                          "estado" => "S300"
                          "issn" => "07351097"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Takayasu arteritis in children&#58; preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Ozen"
                            1 => "A&#46; Duzova"
                            2 => "A&#46; Bakkaloglu"
                            3 => "Y&#46; Bilginer"
                            4 => "B&#46;E&#46; Cil"
                            5 => "M&#46; Demircin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jpeds.2006.10.059"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Pediatr"
                        "fecha" => "2007"
                        "volumen" => "150"
                        "paginaInicial" => "72"
                        "paginaFinal" => "76"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17188618"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Childhood Takayasu arteritis&#58; disease course and response to therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;A&#46; Aeschlimann"
                            1 => "S&#46;W&#46;M&#46; Eng"
                            2 => "S&#46; Sheikh"
                            3 => "R&#46;M&#46; Laxer"
                            4 => "D&#46; Hebert"
                            5 => "D&#46; Noone"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13075-017-1452-4"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Res Ther"
                        "fecha" => "2017"
                        "volumen" => "19"
                        "paginaInicial" => "255"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29166923"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis&#58; Results from a randomised&#44; double-blind&#44; placebo-controlled&#44; phase 3 trial in Japan &#40;the TAKT study&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Y&#46; Nakaoka"
                            1 => "M&#46; Isobe"
                            2 => "S&#46; Takei"
                            3 => "Y&#46; Tanaka"
                            4 => "T&#46; Ishii"
                            5 => "S&#46; Yokota"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2017-211878"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2018"
                        "volumen" => "77"
                        "paginaInicial" => "348"
                        "paginaFinal" => "354"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29191819"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tocilizumab in patients with Takayasu arteritis&#58; a retrospective study and literature review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Loricera"
                            1 => "R&#46; Blanco"
                            2 => "J&#46;L&#46; Hern&#225;ndez"
                            3 => "S&#46; Casta&#241;eda"
                            4 => "A&#46; Humbr&#237;a"
                            5 => "N&#46; Ortego"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Exp Rheumatol"
                        "fecha" => "2016"
                        "volumen" => "34"
                        "paginaInicial" => "44"
                        "paginaFinal" => "53"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23412879/0000009100000006/v1_201912080648/S2341287919301760/v1_201912080648/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "38181"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Scientific letters"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23412879/0000009100000006/v1_201912080648/S2341287919301760/v1_201912080648/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287919301760?idApp=UINPBA00005H"
]
Share
Journal Information
Vol. 91. Issue 6.
Pages 411-413 (1 December 2019)
Vol. 91. Issue 6.
Pages 411-413 (1 December 2019)
Scientific Letter
Open Access
Takayasu arteritis of atypical presentation. Tocilizumab as an alternative therapeutic option
Arteritis de Takayasu de presentación atípica. Tocilizumab como alternativa terapéutica
Visits
3958
Zaira Cubiles Arilloa,
Corresponding author
zaira915@gmail.com

Corresponding author.
, Esmeralda Núñez Cuadrosb, Verónica Martínez Riverac, José Manuel González Gómezd, Victorio Cuenca Peiróe
a Unidad de Gestión Clínica de Pediatría, Hospital Materno Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain
b Unidad de Reumatología Pediátrica, Unidad de Gestión Clínica de Pediatría, Hospital Materno Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain
c Unidad de Nefrología Pediátrica, Unidad de Gestión Clínica de Pediatría, Hospital Materno Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain
d Unidad de Cuidados Intensivos Pediátricos, Unidad de Gestión Clínica de Cuidados Críticos y Urgencias Pediátricas, Hospital Materno Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain
e Unidad de Cardiología Pediátrica, Unidad de Gestión Clínica de Pediatría, Hospital Materno Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. EULAR/PRINTO/PRES criteria for childhood Takayasu arteritis.
Full Text
Dear Editor:

Takayasu arteritis (TA) is a granulomatous large vessel vasculitis that is infrequent in children. It usually has onset with headache, fever, abdominal pain or hypertension (HTN). In rare cases, onset occurs with heart failure, which has only been described in 18% of paediatric cases. There has been recent evidence of the involvement of interleukin-6 (IL-6) in its pathogenesis, whose levels appear elevated in serum and the arterial wall.1

The diagnosis of TA requires the presence of angiographic abnormalities in addition to at least 1 out of 5 criteria (EULAR/PRINTO/PRES criteria, Table 1).2 Although computed tomography angiography (CTA) is the gold standard of imaging, as it allows visualization of blood flow and the extent of collateralization, it does not provide any information about the arterial wall. Thus, a magnetic resonance angiography (MRA) is also useful to assess abnormalities of the vessel wall, and its results correlate to clinical manifestations and inflammatory marker levels. Positron emission tomography/computer tomography (PET-CT) is not indicated for routine assessment, but it may be useful in patients with negative inflammatory markers.2

Table 1.

EULAR/PRINTO/PRES criteria for childhood Takayasu arteritis.

Angiographic abnormalities (conventional, CT or MR imaging) of the aorta or its main branches and pulmonary arteries showing aneurysm/dilatation, narrowing, occlusion or thickened arterial wall not due to fibromuscular dysplasia or similar causes (mandatory criterion) plus one of the following 5 criteria: 
1. Pulse deficit or claudication: lost/decreased/unequal peripheral artery pulses or claudication (focal muscle pain induced by physical activity) 
2. Blood pressure discrepancy: discrepancy of four limb systolic blood pressure> 10mmHg difference in any limb 
3. Bruits: audible murmurs or palpable thrills over large arteries 
4. Hypertension: systolic/diastolic blood pressure greater than 95th percentile for height 
5. Acute phase reactants: ESR>20mm per first hour or any value of CRP above normal (according to the local laboratory) 

Treatment is delivered in 2 phases: induction and maintenance. In case of haemodynamic instability, the induction phase consists of steroids delivered by intravenous pulse initially followed by oral administration combined with an immunosuppressive agent (cyclophosphamide or methotrexate).3 The agents used in the maintenance phase include methotrexate, mycophenolate mofetil or azatioprine.3 In recent years, new treatments have been proposed for refractory cases.2,4–6

We present the case of a patient with TA with onset of heart failure that eventually required biological therapy with anti-IL6.

The patient was a girl aged 11 years presenting with vomiting and abdominal pain with onset 10 days prior associated with asthenia of a few weeks’ duration. The physical examination revealed pallor in the skin and mucosae, acral coldness, difficulty breathing, hypoventilation and bibasilar crackles, a gallop rhythm (heart rate, 140 bpm), an oxygen saturation (SatO2) of 90% and hepatomegaly. The left radial and brachial pulses were absent, with a blood pressure (BP) of 80/50 in the left arm (below the 50th percentile) and 140/100 in the right arm (above the 99th percentile). The salient laboratory features were a haemoglobin concentration (Hb) of 9.9g/dL, a platelet count of 636000/mm3 and a C-reactive protein (CPR) level of 20mg/L. The chest radiograph revealed cardiomegaly with signs of acute pulmonary oedema, and the electrocardiogram featured signs of atrial enlargement and left ventricular hypertrophy.

The patient was admitted to the PICU with a diagnosis of acute heart failure and assessed by means of an echocardiogram that revealed severe systolic failure (forced expiratory volume in 1 second [FEV1], 20%) and mild mitral valve regurgitation. Haemodynamic support was initiated with milrinone, diuretics and levosimendan, and respiratory support with BIPAP, to which the patient responded favourably.

An abdominal ultrasound examination revealed signs of aortitis, and since TA was suspected, the investigation was completed with a CT angiogram (Fig. 1A) that showed thickening of the left subclavian artery with significant stenosis and narrowing at the outlet of the left vertebral artery with collateralization, as well as thickening in segments of the thoracic and abdominal aorta and stenosis of the right renal arteries. Magnetic resonance angiography confirmed the acute involvement of the subclavian and vertebral arteries, and the chronic involvement of the aorta and its branches. The patient received a diagnosis of TA type V and started treatment with boluses of methylprednisolone at a dose of 30mg/kg for 3 days (followed by prednisone at a dose of 2mg/kg/day) and intravenous cyclophosphamide at a dose of 500mg/m2 every 3 weeks, which achieved normalization of laboratory parameters after the second dose. The patient's blood pressure remained above the 99th percentile despite a combination of 6 drugs, so, following performance of an arteriogram (Fig. 1B), the patient underwent a right renal artery angioplasty that allowed the discontinuation of 4 drugs and achieved adequate control of the blood pressure. Two months later, there was evidence of elevation of CRP (46mg/L), the ESR (77mm/h) and serum levels of IL-6 (29.4pg/mL), so after administration of 5 doses of cyclophosphamide, treatment was initiated with anti-IL-6 (tocilizumab iv 8mg/kg every 2 weeks). The patient exhibited a good response after 2 doses, with normalization of laboratory tests and a decrease in the levels of IL-6 (35pg/mL). Twelve months later, the patient was asymptomatic, with a FEV1 70% without treatment with antihypertensive drugs, so, on confirmation of stabilization by imaging, the interval between doses of tocilizumab was increased to 3 weeks.

Figure 1.

(A) Computed tomography angiogram. Stenosis of left subclavian and vertebral arteries, abdominal aorta and right renal arteries. (B) Arteriogram of the aorta. Right kidney with renal artery bifurcation and critical stenosis in the ostium, and left kidney with no signs of stenosis of the renal artery.

(0.12MB).

In addition to the control of HTN, which may be complicated and in some cases require invasive interventions such as renal artery angioplasty,4 the patient must remain under strict monitoring of other cardiovascular risk factors, such as hypercholesterolemia and hypercoagulability. Our patient required rosuvastatin and acetylsalicylic acid.

The challenge in the management of TA is to differentiate between the active and chronic phases, as there are no specific markers of disease activity. The sensitivity and the specificity of CRP and ESR values are low, so other biomarkers are currently being investigated, such as matrix metalloproteinases (MMPs), vascular cell adhesion proteins (VCAM), the inverted CD4/CD8 ratio and pentraxin 3.5 However, there is evidence of a correlation between the levels of IL-6 and disease activity, which suggests that this cytokine may be a useful target for treatment.1,5,6

Although conventional treatment continues to be widespread, several case series have been published that demonstrate the effectiveness of biological agents such as anti-TNF-α (infliximab/adalimumab) or anti-IL6 (tocilizumab).4–6 These studies have reported a mean time to resolution of symptom of 3 months in the absence of severe side effects, in addition to allowing a reduction of the steroid dose.

References
[1]
A.J. Mathew, R. Goel, S. Kumar, D. Danda.
Childhood-onset Takayasu arteritis: an update.
Int J Rheum Dis, 19 (2016), pp. 116-126
[2]
S. Ozen, A. Pistorio, S.M. Lusan, A. Bakkaloglu, T. Herlin, R. Brik, et al.
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.
Ann Rheum Dis, 69 (2010), pp. 798-806
[3]
S. Ozen, A. Duzova, A. Bakkaloglu, Y. Bilginer, B.E. Cil, M. Demircin, et al.
Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate.
J Pediatr, 150 (2007), pp. 72-76
[4]
F.A. Aeschlimann, S.W.M. Eng, S. Sheikh, R.M. Laxer, D. Hebert, D. Noone, et al.
Childhood Takayasu arteritis: disease course and response to therapy.
Arthritis Res Ther, 19 (2017), pp. 255
[5]
Y. Nakaoka, M. Isobe, S. Takei, Y. Tanaka, T. Ishii, S. Yokota, et al.
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Ann Rheum Dis, 77 (2018), pp. 348-354
[6]
J. Loricera, R. Blanco, J.L. Hernández, S. Castañeda, A. Humbría, N. Ortego, et al.
Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review.
Clin Exp Rheumatol, 34 (2016), pp. 44-53

Please cite this article as: Cubiles Arillo Z, Núñez Cuadros E, Martínez Rivera V, González Gómez JM, Cuenca Peiró V. Arteritis de Takayasu de presentación atípica. Tocilizumab como alternativa terapéutica. An Pediatr (Barc). 2019;91:411–413.

Copyright © 2019. Asociación Española de Pediatría
Download PDF
Idiomas
Anales de Pediatría (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?